PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35545150-0	2022	Interaction of the preferential D3 agonist (+)PHNO with dopamine D3-D2 receptor heterodimers and diverse classes of monoamine receptor: relevance for PET imaging.	naxagolide	46-50	iodothyronine deiodinase 3	Homo sapiens	65-67	
35545150-1	2022	(+)-4-Propyl-9-hydroxynaphthoxazine ((+)PHNO) is a high affinity, preferential dopamine D3 versus D2 agonist employed in view of its high specificity and excellent signal-to-noise ratio as a radiotracer for positron emission tomography (PET) imaging.	naxagolide	40-44	iodothyronine deiodinase 3	Homo sapiens	88-90	
35545150-6	2022	In binding assays with membranes derived from cells co-expressing hD3 and hD2L receptors and labeled with (3H)Nemonapride or (3H)Spiperone, the proportion of high affinity binding sites recognized by (+)PHNO was higher than an equivalent mixture of membranes from cells expressing hD3or hD2L receptors, suggesting that (+)PHNO promotes formation of hD3-hD2L heterodimers.	naxagolide	203-207	iodothyronine deiodinase 3	Homo sapiens	66-69	
35545150-6	2022	In binding assays with membranes derived from cells co-expressing hD3 and hD2L receptors and labeled with (3H)Nemonapride or (3H)Spiperone, the proportion of high affinity binding sites recognized by (+)PHNO was higher than an equivalent mixture of membranes from cells expressing hD3or hD2L receptors, suggesting that (+)PHNO promotes formation of hD3-hD2L heterodimers.	naxagolide	203-207	iodothyronine deiodinase 3	Homo sapiens	281-284	
35545150-6	2022	In binding assays with membranes derived from cells co-expressing hD3 and hD2L receptors and labeled with (3H)Nemonapride or (3H)Spiperone, the proportion of high affinity binding sites recognized by (+)PHNO was higher than an equivalent mixture of membranes from cells expressing hD3or hD2L receptors, suggesting that (+)PHNO promotes formation of hD3-hD2L heterodimers.	naxagolide	203-207	iodothyronine deiodinase 3	Homo sapiens	349-352	
35545150-7	2022	Further, in cells co-expressing hD3 and hD2L receptors, (+)PHNO showed higher efficacy for inhibiting forskolin stimulated adenylyl cyclase and inducing adenylyl cyclase super-sensitization than in cells transfected with only hD2L receptors.	naxagolide	59-63	iodothyronine deiodinase 3	Homo sapiens	32-35	
35545150-8	2022	In conclusion, (+)PHNO is a potent agonist at hD4.4, h5-HT1A and h5-HT7 as well as hD3 and hD2L receptors, and it potently activates dopamine hD3-hD2L heterodimers.	naxagolide	18-22	iodothyronine deiodinase 3	Homo sapiens	83-86	
35545150-8	2022	In conclusion, (+)PHNO is a potent agonist at hD4.4, h5-HT1A and h5-HT7 as well as hD3 and hD2L receptors, and it potently activates dopamine hD3-hD2L heterodimers.	naxagolide	18-22	iodothyronine deiodinase 3	Homo sapiens	142-145	
16088951-0	2005	Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors.	naxagolide	48-52	iodothyronine deiodinase 3	Homo sapiens	82-100	
16088951-3	2005	The K(i) values for the human cloned D2(High) and D3(High) receptors, respectively, were 19 and 9 nM for pramipexole, 0.24 and 0.6 nM for +PHNO, 0.7 and 1.3 nM for bromocriptine, 0.5 and 2.6 nM for apomorphine, and 0.09 and 0.25 nM for (-)N-propylnorapomorphine.	naxagolide	139-143	iodothyronine deiodinase 3	Homo sapiens	50-68	
16088951-5	2005	The D3(High) receptors are less selectively occupied by +PHNO, bromocriptine, apomorphine, and -NPA.	naxagolide	57-61	iodothyronine deiodinase 3	Homo sapiens	4-22